EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Fc-engineering for improved cancer immunotherapy

Ella Borgman iD, Camille Le Gall iD, Hidde Ploegh iD, Novalia Pishesha iD

Biochemical Society Transactions · 26.08.2026 · 54 (8) · 1117-1130

DOI: 10.1042/bst20250554 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochemical Society Transactions, online erschienen am 20.08.2026. Verfasst von Ella Borgman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Harvard College, Cambridge, Massachusetts, U.S.A. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Protein Engineering, Immunoglobulin Fc Fragments. Die Arbeit nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Rheumatology Research Foundation (RRF), HHS | National Institutes of Health (NIH), NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Monoclonal antibodies have revolutionized cancer therapy, with approved therapeutics belonging predominantly to the immunoglobulin G (IgG) class. These IgGs mediate antitumor effects predominantly through engagement of Fcγ receptors on immune cells. This engagement results in therapy-activating Fc effector functions such as antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and complement-dependent cytotoxicity. Limitations nonetheless include suboptimal effector engagement and adverse immunological side effects. These drawbacks have driven the search for and optimization of Fc-engineering strategies, including Fc mutations, glycan modification, and choice of Ig isotype, to enhance therapeutic efficacy and tailor immune interactions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsImmunotherapyProtein EngineeringImmunoglobulin Fc FragmentsHumansAnimalsAntibodies, MonoclonalAntibody-Dependent Cell CytotoxicityImmunoglobulin GReceptors, IgG

Stichwörter der Autor:innen

antibodiescancerprotein engineering

Substanzen

Immunoglobulin Fc FragmentsAntibodies, MonoclonalImmunoglobulin GReceptors, IgG

Autor:innen und Institutionen

  • Harvard College, Cambridge, Massachusetts, U.S.A.
  • Division of Immunology, Boston Children's Hospital, Boston, Massachusetts, U.S.A.
  • Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, U.S.A.
  • Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, Massachusetts, U.S.A.

ORCID-Profile: Ella Borgman, Camille Le Gall, Hidde Ploegh, Novalia Pishesha

Förderung

  • Rheumatology Research Foundation (RRF)
  • HHS | National Institutes of Health (NIH)
  • NCI NIH HHS
  • Boston Children's Hospital (BCH)
  • Breakthrough T1D (JDF)
  • American Heart Association (AHA)
  • Lupus Research Alliance (LRA)
  • Charles H. Hood Foundation (CHF)

Zitieren

APA

Borgman, E., Le Gall, C., Ploegh, H., & Pishesha, N. (2026). Fc-engineering for improved cancer immunotherapy. Biochemical Society Transactions, 54(8), 1117-1130. https://doi.org/10.1042/bst20250554

Vancouver

Borgman E, Le Gall C, Ploegh H, Pishesha N. Fc-engineering for improved cancer immunotherapy. Biochemical Society Transactions. 2026;54(8):1117-1130. doi:10.1042/bst20250554

BibTeX
@article{Borgman2026,
  author = {Borgman, Ella and Le Gall, Camille and Ploegh, Hidde and Pishesha, Novalia},
  title = {Fc-engineering for improved cancer immunotherapy},
  journal = {Biochemical Society Transactions},
  year = {2026},
  volume = {54},
  number = {8},
  pages = {1117--1130},
  doi = {10.1042/bst20250554}
}
Kostenlos starten →